Search | Clinical Trials Finder

Conditions: Infantile Hemangioma
Interventions: Propranolol three times a day, Propranolol twice a day, Timolol; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Up to 18 Months
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: DNA Nat-B env, DNA CON-S env, DNA Mosaic env, MVA-CMDR, Placebo for DNA Nat-B env, Placebo for DNA CON-S env, Placebo for DNA Mosaic env, Placebo for MVA-CMDR; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more

Conditions: Moderate to Severe Atopic Dermatitis
Interventions: Rezpegaldesleukin, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 28
States / cities: Bryant, Arkansas • Fountain Valley, California • Los Angeles, California + 22 more

Conditions: Malaria
Interventions: D/ChAd63-CA, D/ChAd63-CAT, Infectivity Control (IC) Group; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Bethesda, Maryland • Silver Spring, Maryland

Conditions: Rotator Cuff Tear Arthropathy
Interventions: Ibuprofen, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Total Hip Arthroplasty
Interventions: Quadratus Lumborum Block (QLB), Standard of Care; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Stroke
Interventions: WATCHMAN LAAC Device Implant, Single Antiplatelet Therapy or No Therapy (Control); Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 71
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more

Conditions: Spine Fusion, NSAID (Non-Steroidal Anti-Inflammatory Drug), Postoperative Pain
Interventions: Naproxen 500 Mg, Ketorolac, OxyCODONE 5 mg Oral Tablet, Metaxalone 800 MG; Drug
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Overactive Bladder
Interventions: Fesoterodine, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 963 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 112
States / cities: Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 99 more

Conditions: Labor Dystocia, Labor Induction, Labor Augmentation
Interventions: Calcium Carbonate 500 MG, Standard Dose Synthetic Pitocin; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Medication Adherence
Interventions: Nurse Coach Intervention; Behavioral
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Multiple Sclerosis
Interventions: Functional Balance Intervention, Stretching; Behavioral
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: IV Atropine and Fentanyl Premedication Arm, IV Normal Saline Placebo Arm; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 0 Hours to 72 Hours
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
Interventions: Acalabrutinib, Investigator's choice of treatment; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Charlotte, North Carolina • Columbus, Ohio • Philadelphia, Pennsylvania

Conditions: Cirrhosis, Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Covert Hepatic Encephalopathy
Interventions: 25% IV albumin, Placebo; Biological · Other
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hepatitis B
Interventions: INO-1800, INO-9112, Nucleos(t)ide Analogue Treatment; Biological · Drug
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 7
States / cities: San Diego, California • Miami, Florida • Manhasset, New York + 4 more

Conditions: Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)
Interventions: Busulfan, Cyclophosphamide, Fludarabine, rabbit ATG, G-CSF, Peripheral blood stem cell; Drug · Biological
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 3 Months and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 3
States / cities: New York, New York • Cincinnati, Ohio • Seattle, Washington

Conditions: Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
Interventions: AADvac1, Donanemab; Drug
Lead sponsor: Paul S. Aisen; Other
Eligibility: 50 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: San Francisco, California • Providence, Rhode Island • Nashville, Tennessee

Conditions: Psoriasis
Interventions: 80 mg ixekizumab Dosing Regimen, 50 mg etanercept, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 41
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 38 more

Conditions: Crohn's Disease
Interventions: Guselkumab, Golimumab, JNJ-78934804, Placebo; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 703 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 90
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 79 more

Conditions: Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder
Interventions: Booster Treatment, No-Booster, No intervention, Treatment As Usual; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 6 Years to 11 Years
Enrollment: 254 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 2
States / cities: Cincinnati, Ohio • Pittsburgh, Pennsylvania

Conditions: Multifocal Motor Neuropathy
Interventions: ARGX-117, Placebo; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 13
States / cities: Scottsdate, Arizona • San Francisco, California • Washington D.C., District of Columbia + 10 more

Conditions: Acute Upper Respiratory Tract Infection
Interventions: Mucinex, Immediate-release Guaifenesin, Placebo; Drug
Lead sponsor: Reckitt Benckiser LLC; Industry
Eligibility: 12 Years and older
Enrollment: 2,810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 43
States / cities: Hoover, Alabama • Bell Gardens, California • Harbor City, California + 38 more

Conditions: Polymyalgia Rheumatica
Interventions: Secukinumab 300 mg, Secukinumab 150 mg, Placebo to secukinumab; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 100 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 22
States / cities: Avondale, Arizona • Peoria, Arizona • Phoenix, Arizona + 17 more

Search by objective public record fields.

Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults

Effect of Ibuprofen on Postoperative Opiate Medication Use and Shoulder Functional Outcomes

Quadratus Lumborum Block Versus Control for Total Hip Arthroplasty

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

Pain Control After Lumbar Spine Fusion

A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

Calcium Carbonate to Augment Labor Contractions

Telehealth-based Strategies to Increase Oral Chemotherapeutic Agent Medication Adherence

Functional Balance Intervention in Multiple Sclerosis

Premedication for Less Invasive Surfactant Administration Study (PRELISA)

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

HEAL STUDY (Hepatic Encephalopathy and Albumin Study)

Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Alzheimer's Tau Platform: Regimen A - AADvac1

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

Resources to Enhance the Adjustment of Children (REACH)

A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy

Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)